Zydus On Acquisitions, $100m Specialty Biz Target, gAsacol Competition
No Revlimid Sales In Q2
Zydus is still on the look out for deals post the recent acquisition of UK-based LiqMeds group as it sets a $100m sales target from specialty/rare disease products. Meanwhile, US revenues are seen stabilizing with new launches, even as lack of Revlimid sales in Q2 led to a 24% drop over the previous quarter.
You may also be interested in...
Plus deals involving Abliva/Owl, Selecta/Cartesian, Novo Nordisk/Genevant, AbbVie/Aldeyra and more.
Sun Pharma sees all time high market share and prescription trends in the US for key specialty products and remains upbeat on the prospects of deuruxolitinib for alopecia areata. The company also isn’t ruling out a potential comeback, at least not yet, for a higher dose version of the JAK1/2 inhibitor.
Sun delivered an exceptional Q2 performance, marred by a 9% decline in its US business due to a significant drop in lenalidomide sales.